News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Optimal Medical Therapy Underprescribed, Discontinued Early in NSTE ACS
August 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TCTMD -- An analysis of patients who have non-ST-segment-elevation acute coronary syndromes (NSTE ACS) and the physicians who treat them suggests that optimal medical therapy frequently is not prescribed, even for those at intermediate to high risk.
Twitter
LinkedIn
Facebook
Email
Print